NVCT Nuvectis Pharma

Watchlist

10.375

+0.455+4.59%

Close 02/03 16:00 ET

High

10.620

Open

9.820

Turnover

1.05M

Low

9.710

Pre Close

9.920

Volume

102.48K

Intraday

Price Forecast

Comment

Announcement

Nuvectis Pharma Launches Collaboration Project for Early Trial of NXP800 in Ovarian Cancer in Europe, US; Shares Rise
12:27 PM EST, 01/04/2023 (MT Newswires) -- Nuvectis Pharma (NVCT) said Wednesday it has entered a collaboration project with the GOG Foundation and the European Network of Gynecological Oncology Trial
01-04 12:28 ET
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Nuvectis Pharma (NVCT)
01-04 10:15 ET
Nuvectis Pharma Announces Collaboration With ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr. Ramez Eskander
01-04 08:01 ET
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Sees Significant Decline in Short Interest
Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Rating) saw a significant drop in short interest in December. As of December 15th, there was short interest totalling 11,200 shares, a drop of 30.0% from the
01-01 01:01 ET
Is Nuvectis Pharma, Inc. (NASDAQ:NVCT) Trading At A 33% Discount?
12-31-2022 08:22:50 ET
Nuvectis Pharma Wins FDA Fast Track Status for Cancer Candidate
12-01-2022 01:48:58 ET
Nuvectis Pharma's Ovarian Cancer Therapy Receives US FDA's Fast Track Designation; Shares Rise
10:25 AM EST, 12/01/2022 (MT Newswires) -- Nuvectis Pharma (NVCT) said Thursday that the US Food and Drug Administration has granted fast-track designation to NXP800 for the treatment of platinum-resi
12-01-2022 10:29:49 ET
Nuvectis Gets FDA Fast-Track Designation for NXP800 in Ovarian Cancer >NVCT
By Colin Kellaher Nuvectis Pharma Inc. on Thursday said the U.S. Food and Drug Administration granted fast-track designation to its NXP800 drug candidate in a form of ovarian cancer. The Fort Lee, N
12-01-2022 08:16:26 ET
Nuvectis Pharma Announces FDA Granted FTD to NXP800
12-01-2022 08:15:57 ET
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of innovative precision medi
12-01-2022 08:06:37 ET

Company Overview More

Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

CEO： Mr. Ron Bentsur

Market： NASDAQ

Listing Date： 02/04/2022

Paper Trade More

Direction

Buy

Sell

Types

LMT Order

Price

QTY

Amount

Get Started

Hot List

TradeSearchNews

SymbolLatest price%Chg

Watchlist